Concepedia

A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC

Lei Wang, Yongzhong Luo, Shengxiang Ren, Zhihong Zhang, Anwen Xiong, Chunxia Su, Jin Zhou, Xinmin Yu, Yanping Hu, Xiaodong Zhang,

Journal of Thoracic Oncology · 2023 · 58 citations · 23 references

DOIFull text

Open access

Concepts

References

23

Cancer statistics, 2022

Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2022 · 18.2K citations · Full text

, , +16

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

, , +17

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.8K citations · Full text

, , +16

Cancer treatment and survivorship statistics, 2022

Kimberly D. Miller, Letícia Nogueira, Theresa P. Devasia et al. · CA A Cancer Journal for Clinicians · 2022 · 3.7K citations · Full text

, , +17

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Alexander Luft, David Vicente et al. · New England Journal of Medicine · 2018 · 3.6K citations · Full text

, , +17